Dosing underway in third cohort of OPTIC trial of ADVM-022

The first patient has been dosed in the third cohort of the OPTIC phase 1 clinical trial of ADVM-022, an intravitreal gene therapy for the treatment of wet age-related macular degeneration, according to a press release from Adverum Biotechnologies.
Patients in this cohort are receiving a single injection of ADVM-022 at a dose of 2 × 1011 vg per eye.
“This expansion of OPTIC will generate important clinical data to support the further development of ADVM-022,” Aaron Osborne, MBBS, chief medical officer of Adverum, said in the release. “Based on (Read more...)

Full Story →